Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L5 peptide
- Development stage
- Preclinical
- Lead developer
- RayzeBio
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
**L5 peptide** is a 14-amino acid peptide (Arg-Leu-Asn-Val-Gly-Gly-Thr-Tyr-Phe-Leu-Thr-Thr-Arg-Gln) that targets Glypican 3 (GPC3), a plasma membrane heparan sulfate proteoglycan overexpressed in hepatocellular carcinoma (HCC). It is used in a pretargeting approach to enhance magnetic resonance (MR) imaging for diagnosing HCC by binding to GPC3-expressing cells. The peptide is often used in conjunction with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles for MR imaging.
- Other names
- L5L-5L 5RLNVGGTYFLTTRQ
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on L5 peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L5 peptide.